美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Corgi All World 2x Daily ETF

23.82

-0.1769-0.74%

盤後：23.820.00000.00%16:10 EDT

成交量：147

成交額：3,528

市值：35.74萬

市盈率：- -

高：23.82

開：23.70

低：23.70

收：24.00

52周最高：25.58

52周最低：20.48

股本：1.50萬

流通股本：1.50萬

量比：0.64

換手率：0.98%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

【券商聚焦】中信建投：CXO 行業復甦明確，海內外醫藥投融資同步回暖

中信建投：CXO板塊Beta穩中向好，AI製藥大有可為

CXO巨頭爆量上漲！開盤45分鐘成交120億元，超上日全天！規模最大醫療ETF（512170）創本輪反彈新高

反轉信號已現，藥明只是導火索

創新藥產業鏈全線走強！CXO巨頭半年淨利首超百億元，績後飆漲逾10%！創新藥龍頭回暖，520880放量上探2.58%

港股異動 | CRO概念股漲幅居前近期多家海外MNC與CXO披露中報盈喜並上調全年指引

業績炸裂！全年收入劍指605億，藥明康德AH股價狂飆！高「CXO含量」港股通醫療ETF華寶（159137）暴升逾5%！

再次突破半年線！全市場規模最大醫療ETF（512170）摸高1.54%，AI醫療、CXO攜手拉漲！港股通醫療同步走強

【券商聚焦】中信建投：CXO個股訂單加速兑現，行業內需企穩回升

醫藥外包概念全線揚升昭衍新藥(06127)漲7.93% 機構指CXO景氣進入中報業績兑現期

中信建投：2026年國內CRO/CDMO行業的新簽訂單及業績會加速增長，帶動CXO產業鏈進入新一輪發展階段

中信建投：CXO板塊Beta穩中向好個股訂單加速兑現

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/WX/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"WX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"WX\",,,,,undefined,":{"symbol":"WX","market":"US","secType":"STK","nameCN":"Corgi All World 2x Daily ETF","latestPrice":23.8247,"timestamp":1789588800000,"preClose":24.0016,"halted":0,"volume":147,"hourTrading":{"tag":"盘后","latestPrice":23.8247,"preClose":23.8247,"latestTime":"16:10 EDT","volume":6,"amount":142.698804,"timestamp":1789589404607,"change":0,"changeRate":0,"amplitude":0.005234},"delay":0,"changeRate":-0.007370341977201513,"floatShares":15000,"shares":15000,"eps":0,"marketStatus":"盤後交易","change":-0.1769,"latestTime":"09-16 19:14:32 EDT","open":23.7,"high":23.8247,"low":23.7,"amount":3528,"amplitude":0.005195,"askPrice":35.53,"askSize":200,"bidPrice":11.85,"bidSize":200,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":4,"adr":0,"exchange":"CBOE","adjPreClose":24.0016,"nav":24.22,"aum":363300,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":23.8247,"preClose":23.8247,"latestTime":"16:10 EDT","volume":6,"amount":142.698804,"timestamp":1789589404607,"change":0,"changeRate":0,"amplitude":0.005234},"volumeRatio":0.644172},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"WX\",,,,,undefined,":{"symbol":"WX","floatShares":15000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.644172,"shares":15000,"dividePrice":0,"high":23.8247,"amplitude":0.005195,"preClose":24.0016,"low":23.7,"week52Low":20.48,"pbRate":"--","week52High":25.58,"institutionHeld":0,"latestPrice":23.8247,"eps":0,"divideRate":0,"volume":147,"delay":0,"ttmEps":0,"open":23.7,"prevYearClose":24.72,"prevWeekClose":24.6313,"prevMonthClose":24.9073,"prevQuarterClose":23.5672,"fiveDayClose":24.6388,"twentyDayClose":24.8296,"sixtyDayClose":23.76},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/WX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"WX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"WX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"WX\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657657002","title":"【券商聚焦】中信建投：CXO 行業復甦明確，海內外醫藥投融資同步回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657002","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657002?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 09:04","pubTimestamp":1785978243,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投表示，国内CXO行业经历22-24年的调整阶段后，受益海外投融资率先回暖，24年国内头部CXO公司海外订单展现复苏态势，随着25年国内创新药资产实现大规模对外授权，带动国内投融资25H2持续复苏，行业内需同样企稳回升。26年至今国内创新药行业的长期结构性机会持续兑现，国内投融资持续改善，新药物形式赛道持续火热并进一步放量，该机构认为26年国","market":"sg","thumbnail":"https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987586","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","159938","CXO","601066","BK0276","BK1515","09939","BK1161","WX","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657572212","title":"中信建投：CXO板塊Beta穩中向好，AI製藥大有可為","url":"https://stock-news.laohu8.com/highlight/detail?id=2657572212","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657572212?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 07:41","pubTimestamp":1785973273,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ARTY","QTOC","CXO","AIPO","CHAT","AGIX","VTHR","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657591587","title":"CXO巨頭爆量上漲！開盤45分鐘成交120億元，超上日全天！規模最大醫療ETF（512170）創本輪反彈新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2657591587","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657591587?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 10:35","pubTimestamp":1785897300,"startTime":"0","endTime":"0","summary":"CXO巨头药明康德重磅财报继续发酵！8月5日早盘，药明康德A股爆量上行，盘初一度续涨逾6%，截至10：15涨4.6%，成交超120亿元，超越上日全天，跻身A股成交额前五！全市场规模最大医疗ETF华宝同步上扬，场内价格创本轮反弹新高！数据显示，药明康德为医疗ETF华宝第一大重仓股，最新持仓占比达12.69%。高效参与CXO交易，关注两大“利器”：医疗ETF华宝：全市场规模最大医药医疗类ETF，聚焦医疗器械+医疗服务，兼顾AI医疗概念。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-05/doc-inimfshm5200987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["512170","WX","CXO","159828"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657619592","title":"反轉信號已現，藥明只是導火索","url":"https://stock-news.laohu8.com/highlight/detail?id=2657619592","media":"虎嗅APP","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657619592?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 07:58","pubTimestamp":1785887880,"startTime":"0","endTime":"0","summary":"2026年2季度，共有793个机构投资者披露持有药明康德A股，合计持股量达10.93亿股，占总股本的36.64%。2026年6月末，药明康德有664.3亿元的在手订单，同比增长25.2%，超1季度23.6%的增幅。行业反转信号现，药明只是导火索此前市场对CXO行业最大的疑虑是“订单有改善，但利润没出来”，但2026年中报正在打破这个质疑。2026年6月8日，药明康德被新增列入。药明康德已于6月11日提起诉讼，目前尚未裁决。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MTQzMjE1NjQwMQ==&mid=2656191578&idx=3&sn=832b803cb4237ffa6df707ef821c3501&chksm=671c8735cca01ad5e39d65b82e0f5f3051390a006108bde4292a28549d69473cd36634de313a&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656589128","title":"創新藥產業鏈全線走強！CXO巨頭半年淨利首超百億元，績後飆漲逾10%！創新藥龍頭回暖，520880放量上探2.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656589128","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656589128?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 11:07","pubTimestamp":1785812820,"startTime":"0","endTime":"0","summary":"8月4日早盘，创新药产业链全线走强，港股一马当先！港股通创新药龙头多股回暖，百济神州、石药集团、康方生物、中国生物制药等批量涨超1%，100%创新药研发标的——港股通创新药ETF华宝盘初放量上探2.58%！CXO巨头药明康德半年度业绩大增，绩后跳空高开，港股股价一度暴涨超14%！8月3日晚间，药明康德披露了上半年业绩，超出市场预期。这是公司净利润首次在上半年突破百亿元大关。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-04/doc-inimchzm4203295.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","06978","520880","BK1161","MEDX","WX","BK1574","IBBQ","LNGR","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656158919","title":"港股異動 | CRO概念股漲幅居前 近期多家海外MNC與CXO披露中報盈喜並上調全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2656158919","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656158919?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 11:05","pubTimestamp":1785812703,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，CRO概念股涨幅居前，截至发稿，药明康德涨11.05%，报180.9港元；金斯瑞生物科技涨10.18%，报17.96港元；凯莱英涨7.71%，报117.4港元；药明生物涨3.92%，报40.34港元。消息面上，药明康德公告称，上半年公司实现营业收入288.97亿元，同比增长38.93%；归母净利润110.8亿元，同比增长29.43%。值得注意的是，近期已有多家多家海外MNC与CXO披露中报盈喜并上调全年指引。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475611.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999002463.SGD","BK4585","LU0181495838.USD","LU0140636845.USD","WX","HK0000306701.USD","LU0359202008.SGD","BK1576","KURE","LU0348825331.USD","LU0456846285.SGD","CXO","VXUS","BK1583","LU0348767384.USD","LU0417516902.SGD","LU0708995583.HKD","LU0823426480.USD","LU0516423174.USD","02269","BK4588","LU1720050803.USD","LU1242518931.SGD","LU0052750758.USD","LU1046422090.SGD","01548","LU0516422440.USD","02359","06821","KCAI","LU0588546209.SGD","BK1141","HK0000306685.HKD","LU3063872942.SGD","LU1242518857.USD","LU0456827905.SGD","BK1521","LU0417516738.SGD","LU0039217434.USD","LU0979878070.USD","LU1688375341.USD","LU1794554557.SGD","LU0327786744.USD","LU0856984785.SGD","LU0043850808.USD","BK1610","LU0348766576.USD","LU0516422952.EUR","BK1191","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656958656","title":"業績炸裂！全年收入劍指605億，藥明康德AH股價狂飆！高「CXO含量」港股通醫療ETF華寶（159137）暴升逾5%！","url":"https://stock-news.laohu8.com/highlight/detail?id=2656958656","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656958656?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 09:47","pubTimestamp":1785808020,"startTime":"0","endTime":"0","summary":"药明康德业绩炸裂，CXO板块大受提振！8月4日早盘，药明康德AH股跳空高开，携手狂飙，A股涨停封板，港股一度暴涨超14%。港股通医疗ETF华宝近5成仓位布局CXO，场内价格一度暴涨超5%！全市场规模最大医疗ETF华宝CXO含量近30%，现涨超2%。8月3日晚，药明康德发布半年报，公司上半年实现营业收入288.97亿元，同比增长38.93%；归属于上市公司股东的净利润110.8亿元，同比增长29.43%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-04/doc-inimchzm4134226.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BPRC5H50.USD","LU2242644610.SGD","LU1719994722.HKD","WX","LU2328871848.SGD","LU2495084118.USD","LU0348766576.USD","LU0708995583.HKD","02359","LU1251922891.USD","LU1997244956.HKD","BK1583","LU0320764599.SGD","LU1770034418.SGD","LU1808992512.USD","LU1969619763.USD","LU0700851271.USD","LU1934453819.USD","BK1576","LU2125910500.SGD","LU1303224171.USD","LU0052750758.USD","IE00B543WZ88.USD","LU0348767384.USD","159137","BK0216","IE00B5MMRT66.SGD","LU2045819591.USD","LU1997245177.USD","512170","BK1141","LU1046422090.SGD","LU1997245094.SGD","603259","FLHK","LU1979443071.USD","CXO","LU0456842615.SGD","LU0611395673.USD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655933513","title":"再次突破半年線！全市場規模最大醫療ETF（512170）摸高1.54%，AI醫療、CXO攜手拉漲！港股通醫療同步走強","url":"https://stock-news.laohu8.com/highlight/detail?id=2655933513","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655933513?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 10:52","pubTimestamp":1785466320,"startTime":"0","endTime":"0","summary":"7月31日，A股医疗板块低开高走，全市场规模最大医疗ETF华宝上探1.54%，连续第3日盘中突破半年线！成份股涨跌互现，AI医疗概念领涨，迪安诊断、九安医疗、奕瑞科技齐涨超7%。医疗器械回调，迈瑞医疗、联影医疗跌逾1%。港股通医疗ETF华宝：重仓创新药产业链，48%CXO+20%创新药，兼顾AI医疗、医疗器械等领域稀缺龙头，底层资产是港股，高弹性，T+0。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-07-31/doc-inikshrh9344635.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["VTHR","159891","AIPO","CXO","FLHK","WX","QTOC","ARTY","512170","159828","CHAT","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655724380","title":"【券商聚焦】中信建投：CXO個股訂單加速兑現，行業內需企穩回升","url":"https://stock-news.laohu8.com/highlight/detail?id=2655724380","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655724380?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 09:12","pubTimestamp":1785460332,"startTime":"0","endTime":"0","summary":"26年至今国内创新药行业的长期结构性机会持续兑现，国内投融资持续改善，新药物形式赛道持续火热并进一步放量，该机构认为26年国内CRO/CDMO行业的新签订单及业绩会加速增长，带动CXO产业链进入新一轮发展阶段。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987181","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2778985437.USD","IE00B3M56506.USD","LU2328871848.SGD","BK1515","BK1161","LU0348767384.USD","02196","01789","09688","LU1969619763.USD","LU0348784397.USD","BK1141","BK0276","LU1303224171.USD","01530","LU0540923850.HKD","LU0417516571.SGD","WX","KCE","01099","LU1770034418.SGD","LU0348783233.USD","KURE","LU2476274308.USD","LU2488822045.USD","LU0640798160.USD","601066","06821","BK1191","LU1251922891.USD","IE00B5MMRT66.SGD","03933","LU2476274720.SGD","LU1961090484.USD","LU0348825331.USD","CXO","BK1500","LU0348735423.USD","BK1617","LU1794554557.SGD","06160","09926","02268","LU0634319403.HKD","02367","LU0348827113.USD","BK1585","SG9999004311.SGD","BK1197","02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654095486","title":"醫藥外包概念全線揚升 昭衍新藥(06127)漲7.93% 機構指CXO景氣進入中報業績兑現期","url":"https://stock-news.laohu8.com/highlight/detail?id=2654095486","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654095486?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 10:17","pubTimestamp":1785118673,"startTime":"0","endTime":"0","summary":"消息面上，开源证券新近研究指出，7月以来，康龙化成、昭衍新药、美迪西和药康生物先后发布2026年H1业绩预增公告，从早研到临床前研究，CXO景气周期已逐步进入利润表兑现期。根据医药魔方，2026H1全球创新药一级市场共发生505起融资事件，同比增长6.1%，融资金额达到267.5亿美元，同比增长58.5%。2026H1中国相关交易数量及金额涨势迅猛，总金额达997亿美元。从6月初至今，CXO板块在业绩和订单的支撑下，率先于创新药反弹。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986787","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0140636845.USD","01548","LU2039709279.SGD","159938","03759","BK1141","LU0307460666.USD","SG9999002562.SGD","06127","BK1583","LU0417516738.SGD","09939","LU0516423174.USD","HK0000320264.USD","BK1191","WX","LU0823426308.USD","LU0348766576.USD","03347","LU1242518857.USD","LU0327786744.USD","CXO","LU0039217434.USD","LU0856984785.SGD","01873","LU2125910500.SGD","LU1242518931.SGD","BK1161","LU0348767384.USD","LU0348735423.USD","BK1610","LU0043850808.USD","02359","LU0588546209.SGD","LU0516422440.USD","LU2242644610.SGD","LU0359201612.USD","06821","LU0516422952.EUR","LU1880383366.USD","LU3063872942.SGD","BK0216","HK0000306685.HKD","LU0823426480.USD","LU1046422090.SGD","BK1574","BK1589","603127","KURE","02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653772632","title":"中信建投：2026年國內CRO/CDMO行業的新簽訂單及業績會加速增長，帶動CXO產業鏈進入新一輪發展階段","url":"https://stock-news.laohu8.com/highlight/detail?id=2653772632","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653772632?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 08:20","pubTimestamp":1784852419,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CXO","CDMO","WX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653774203","title":"中信建投：CXO板塊Beta穩中向好 個股訂單加速兑現","url":"https://stock-news.laohu8.com/highlight/detail?id=2653774203","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653774203?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 07:45","pubTimestamp":1784850351,"startTime":"0","endTime":"0","summary":"26年至今国内创新药行业的长期结构性机会持续兑现，国内投融资持续改善，新药物形式赛道持续火热并进一步放量，26年国内CRO/CDMO行业的新签订单及业绩会加速增长，带动CXO产业链进入新一轮发展阶段。随着资金由融资端向CXO逐级传导，叠加板块估值仍处历史较低水平，行业业绩与估值有望持续修复。行业调整基本完成，Beta修复与个股Alpha进入兑现期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471713.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601066","BK0276","WX","CXO"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":52,"code":"91000000","status":"200"}]}}